Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 1009-1021

  Gibson, Todd J ^a   Mccarty, Katie ^b   Mcfadyen, Iain J ^b   Cash, Ethan ^b,d   Dalmonte, Paul ^b   Hinds, Kenneth D ^a   Dinerman, Adam A ^a   Alvarez, Juan C ^b   Volkin, David B ^a,c  

^a Pharmaceutical Development and Manufacturing Sciences   (United States)

^b TransForm Pharmaceuticals   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d ALKERMES INC   (United States)

Author keywords

Formulation; High throughput technologies; IgG; Monoclonal antibody; Polyethylene glycol (PEG); Precipitation; Solubility; Stability

Indexed keywords

BUFFER; IMMUNOGLOBULIN G1; MACROGOL; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; BIOAVAILABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; IMMUNOGENICITY; MONTE CARLO METHOD; MOUSE; NONHUMAN; PH MEASUREMENT; PRECIPITATION; QUANTITATIVE ANALYSIS; SOLUTION AND SOLUBILITY;

EID: 79251581274     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22350     Document Type: Article

References (46)

1. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress induced aggregation of protein therapeutics. Methods Enzymol 309:236-255.
2. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
3. Koren E, Zuckerman A, Mire-Sluis AR. 2002. Immune responses to therapeutic proteins in humans-clinical significance, assessment, and prediction. Curr Pharm Biotech 3:349-360.
4. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:8:E501-E508.
5. Hermeling, S, Crommelin, DJA, Schellekens, H. Jiskoot, W. 2004. Structure-immunogenicity relationship of therapeutic proteins. Pharm Res 21:897-903.
6. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:511-516.
7. Middaugh CR, Volkin DB. 1992. Protein solubility. In Stability of protein pharmaceuticals, part A: Chemical and physical pathways of protein degradation; Ahern TJ, Manning MC, Eds. New York: Plenum Press, pp 109-143.
8. Trevino SR, Scholtz JM, Pace CN. 2008. Measuring and increasing protein solubility. J Pharm Sci 97:4155-4166.
9. Schein CH. 1990. Solubility as a function of protein structure and solvent components. Biotechnology 8:308-317.
10. Bagby S, Tong KI, Ikuru M. 2001. Optimization of protein solubility and stability for protein nuclear magnetic resonance. Methods Enzymol 339:20-41.
11. Golovanov AP, Hautbergue GM, Wilson SA, Lian LY. 2004. A simple method for improving protein solubility and long-term stability. J Am Chem Soc 126:8933-8939.
12. Middaugh CR, Litman GW. 1978. Effect of solutes on the cold induced insolubility of monoclonal cryoimmunoglobulins. J Biol Chem 252:8002-8006.
13. Gagnon P, Mayes T, Danielsson. 1997. An adaptation of hydrophobic interaction chromatography for estimation of protein solubility optima. J Pharm Biomed Anal 16:587-592.
14. Fransson J, Hallen D, Florin-Robertsson E. 1997. Solvent effects on the solubility and physical stability of human insulin-like growth factor I. Pharm Res 14:606-612.
15. Chen BL, Wu X, Babuka SJ, Hora M. 1999. Solubility of recombinant human tissue factor pathway inhibitor. J Pharm Sci 88:881-888.
16. Pohl T. Concentration of proteins and removal of solvents. 1990. Methods Enzymol 182:68-83.
17. Bevan CD, Lloyd RS. 2000. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem 72:1781-1787.
18. Valente J, Verma K, Manning M, Wilson W, Henry C. 2005. Second virial coefficient studies of cosolvent-induced protein self-interaction. Biophys J 89:4211-4218.
19. Middaugh C, Tisel W, Haire R, Rosenberg A. 1979. Determination of the apparent thermodynamic activities of saturated protein solutions. J Biol Chem 254:367-370.
20. Ingham KC. 1990. Precipitation of proteins with polyethylene glycol. Methods Enzymol 182:301-306.
21. Tisel WA, Haire RN, White JG, Rosenberg A, Middaugh CR. 1980. Polyphasic linkage between protein solubility and ligand binding in the hemoglobin-polyethylene glycol system. J Biol Chem 255:8975-8978.
22. Lawson EQ, Schubert CR, Lewis RV, Middaugh CR. 1981. The solubility of bovine lens crystallins. J Biol Chem 256:6523-6525.
23. Annunziata O, Asherie N, Lomakin A, Pande J, Ogun O, Benedek GB. 2002. Effect of polyethylene glycol on the liquid-liquid phase transition in aqueous protein solutions. PNAS 99:14165-14170.
24. Atha DH, Ingham KC. 1981. Mechanism of precipitation of proteins by polyethylene glycols. J Biol Chem 256:12108-12117.
25. Sharma VK, Kalonia DS. 2004. Polyethylene glycol-induced precipitation of interferon alpha-2a followed by vacuum drying: Development of a novel process for obtaining a dry, stable powder. AAPS PharmSci 6:1-14.
26. Stevenson CL, Hageman MJ. 1995. Estimation of recombinant bovine somatotropin solubility by excluded-volume interaction with polyethylene glycols. Pharm Res 12:1671-1676.
27. Harn N, Spitznagel T, Perkins M, Allan C, Shire S, Middaugh CR. Biophysical signatures of monoclonal antibodies. 2010. In Current trends in monoclonal antibody development and manufacturing; Shire S, Gombotz W, Bechtold-Peters K, Andya J, Eds. New York: Springer, 229-246.
28. Gardner CR. 2005. Drug candidate selection: The role of physical chemistry and material science in form and formulation. Bull Tech Gattefosse 98:9-18.
29. Di L, Kerns EH. Profiling drug-like properties in discovery research. Curr Opin Chem Biol 7:402-408 (2003).
30. Hui R, Edwards A. 2003. High throughput protein crystallization. J Struct Biol 142:154-161.
31. Woestenenk EA, Hammarström M, Härd T, Berglund. (2003). Screening methods to determine biophysical properties of proteins in structural genomics. Anal Biochem 318:71-79.
32. Hammarström M, Hellgren N, Van Den Berg S, Berglund H, Härd T. 2002. Rapid screening for improved solubility of small proteins produced as fusion proteins in Escherichia coli. Prot Sci 11:313-321.
33. Reichert JM, Jacob NM, Amanullah A. 2009. Meeting report on second international conference on accelerating biopharmaceutical development. mAbs 1:1-20.
34. Rege K, Pepsin M, Falcon B, Steele L, Heng M. 2005. High-throughput process development for recombinant protein purification. Biotech Bioeng 93:618-630.
35. Stenvall M, Steen J, Uhlén M, Hober S, Ottosson J. 2005. High-throughput solubility assay for purified recombinant protein immunogens. Biochem Biophys Acta 1752:6-10.
36. Nayar R, Manning MC. 2002. High throughput formulation: Strategies for rapid development of stable protein products. In Rationale design of stable formulations; Carpenter JC, Manning MC, Eds. New York: Plenum Publishing 177-198.
37. Capelle MAH, Gurny R, Arvinte T. 2007. High throughput screening of protein formulations: Practical considerations. Europ J Pharm Biopharm 65:131-148.
38. Capelle MAH, Gurny R, Arvine T. 2009. A high throughput protein formulation platform: Case study of salmon calcitonin. Pharm Res 26:118-128.
39. Johnson DH, Parupudi, A, Wilson WW, DeLucas LJ. 2009. High-throughput self-interaction chromatography: Application in protein formulation prediction. Pharm Res 26:296-305.
40. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99:1701-1720.
41. Zhao H, Graf O, Milovic N, Luan X, Bluemel M, Smolny M, Forrer K. 2010. Formulation development of antibodies using robotic system and high throughput laboratory (HTL). J Pharm Sci 99:2279-94.
42. Kreusch S, Schwedler S, Tautkus B, Cumme GA, Horn A. 2003. UV measurements in microplates suitable for high-throughput protein determination. Anal Biochem 313:208-215.
43. Li N, Kessler K, Bass L, Zeng D. 2007. Evaluation of the cIEF280 analyzer as a potential high-throughput tool for formulation development. J Pharm Biomed Anal 43:963-972.
44. Kueltzo LA, Middaugh CR. 2003. Structural characterization of bovine granulocyte colony stimulating factor: Effect of temperature and pH. J Pharm Sci 92:1793-1804.
45. Kueltzo LA, Ersoy B, Darrington T, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92:1805-1830.
46. Sunberg SA. 2000. High-throughput and ultra-high-throughput screening: Solution and cell based approaches. Curr Tr Biotechnol. 11:47-53.